Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | PPARG | P37231 | 8/20 | 0.61 |
| ▸ | PPARA | Q07869 | 5/20 | 0.61 |
| ▸ | TARBP2 | Q15633 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3529543 | 0.90 | PPARG (0.59) | KDM4EPPARGPPARAALDH1A1MAPK1 | |
| SCHEMBL6437060 | 0.84 | KDM4E (0.72) | KDM4EPPARGPPARATARBP2ALDH1A1 | |
| SCHEMBL4893515 | 0.83 | KDM4E (0.70) | KDM4EPPARGPPARATARBP2FFAR1 | |
| SCHEMBL7911544 | 0.82 | FFAR1 (0.59) | KDM4EPPARGPPARAFFAR1KDR | |
| SCHEMBL3590532 | 0.81 | KDM4E (0.70) | KDM4EPPARGPPARAFFAR1KDR | |
| SCHEMBL2930640 | 0.80 | KDM4E (0.74) | KDM4EPPARGPPARATARBP2FFAR1 | |
| SCHEMBL4035110 | 0.78 | KDR (0.67) | PPARGPPARAFFAR1KDRMAPT | |
| SCHEMBL10973001 | 0.77 | HSD17B10 (0.74) | KDM4EPPARGPPARATARBP2ALDH1A1 | |
| SCHEMBL893027 | 0.77 | KDM4E (1.00) | KDM4EPPARGPPARATARBP2FFAR1 | |
| SCHEMBL7906307 | 0.76 | KDM4E (0.56) | KDM4EPPARGPPARAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816385-B2 | Dimeric dicarboxylic acid derivatives, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-10-19 | — | — | US | disclosed |
| EP-1578716-A1 | DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS | NOVO NORDISK A/S (DK) | 2005-09-28 | — | — | EP | disclosed |
| US-20040259950-A1 | Novel compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2004-12-23 | — | — | US | disclosed |
| WO-2004056740-A1 | DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259950-A1 | Novel compounds, their preparation and use | PPARG, PPARA, PPARD | KDM4E 3030/4885PPARG 1/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.